What changed from existing technology?
This study aims to create a consistent way to test human immune cells using different machines, so that results can be compared and used with artificial intelligence.
This study introduces a new framework for creating standardized flow cytometry assays across different platforms, which is essential for improving the reliability and comparability of cell therapy quality assessments.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
arious flow cytometry platforms, sites, and over time remain a major challenge. Method Through a large-scale interlaboratory study (ILS), coordinated by
Abstract ↗OpenAlex author affiliations: Revvity (United States), BD Biosciences (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This framework could be used to improve the consistency and reliability of cell therapy quality assessments across different laboratories and instruments, supporting the development of AI-driven quality control systems.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchStandardizing a human TBMNK cell assay across instrument platforms: a new framework for producing high-quality, AI-ready reference datasetFrontiers in Immunology · Published 2026-09-28 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.